2024药物靶点研究相关试剂3.0

北京义翘神州01药物靶点研究相关试剂5,000+靶向治疗相关重组蛋白药物靶点研究相关试剂药物靶点研究是药物发现和开发的关键。目前，获得临床批准的药物的主要靶点包括酶、G蛋白偶联受体（GPCRs）、CD标志物、转运体、离子通道和核受体。新靶点的发现可以开发新的治疗方法，增加治疗策略的广度，改善患者的治疗效果。蛋白酶表观遗传相关酶细胞治疗靶点流感病毒抗原G蛋白偶联受体（GPCR）细胞因子HIV抗原核受体CD蛋白HCV抗原离子通道蛋白激酶SARS-CoV-2涵盖多个治疗领域肿瘤呼吸系统疾病自身免疫性疾病神经系统疾病炎症性疾病内分泌和代谢疾病心血管疾病骨质疏松症脑血管疾病创伤修复传染性疾病移植排斥消化系统疾病基础研究转化研究药物开发全球5000+客户激酶义翘神州已经开发了高质量的生物试剂，以支持靶点类药物的发现和开发。酶离子通道转运蛋白

CD分子

GPCRs核受体FDA批准的药物中靶点的比例和分类北京义翘神州酶蛋白酶是信号转导和细胞调节不可缺少的蛋白，这其中最常见的激酶和磷酸酶。许多酶都与癌症的发生和发展有着重要的关系。目前，用于治疗多种癌症的小分子激酶抑制剂已在临床治疗中获得了成功。此外，病毒基因组也会转录合成促进病毒基因组复制的酶类（如HIV整合酶和逆转录酶）以及从宿主细胞中释放所需的酶类（如流感病毒神经氨酸酶，这些酶类都是治疗病毒感染的重要的靶点分子。义翘神州开发了多种研究试剂，以支持对酶蛋白作为药物靶点的研究。02药物靶点研究相关试剂20,000+酶相关试剂1,000+重组蛋白2,000+抗体20,000基因/cDNA800+分子qPCR

Primer/IP

Kit/Cell

Lysate覆盖11类种属高质量优惠的价格现货供应高质量酶蛋白The

specific

activity

of

LRRK2

was

determined

to

be

0.7

nmol/min/mg

as

per

activity

assay

protocol

and

was

equivalent

to

5.7

nmol/min/mg

as

per

radiometric

assay.020408010052,00041,60031,20020,80010,4000Activity（RLU）60Protein（ng）重组人LRRK2蛋白(Cat#:

L10-11G)激酶活性已验证The

purity

of

GLK

was

determined

to

be

>80%

by

densitometry.The

specific

activity

of

GLK

was

determined

to

be

44

nmol/min/mg

as

per

activity

assay

protocol

and

was

equivalent

to

103

nmol/min/mg

as

per

radiometric

assay.重组人CDK2/CyclinE1蛋白(Cat#:

C29-18G)激酶活性已验证重组人GLK蛋白(Cat#:

M25-11G)激酶活性已验证0950,000760,000570,000380,000190,0000154560Activity（RLU）30Protein（ng）0

2

4

6

8

10

12

141,000,000800,000600,000400,000200,0000Activity（RLU）Protein（ng）The

specific

activity

of

CDK2/CyclinE1

was

determined

to

be

104

nmol/min/mg

as

per

activity

assay

protocol.1801301007055403525The

purity

of

LRRK2

was

determined

to

be

>80%

by

densitometry.170130957255433426The

purity

of

CDK2/CyclinE1

was

determined

to

be

>90%

by

densitometry.1801301007055403525北京义翘神州03药物靶点研究相关试剂酶蛋白部分激酶蛋白产品列表更多酶类蛋白TAK1-TAB1,

Active

(Cat#:

M15-13G)部分酶蛋白分子The

specific

activity

of

TAK1-TAB1

was

determined

to

be

12nmol/min/mg

as

per

activity

assay

protocol.The

specific

activity

of

PLK1

was

determined

to

be42

nmol/min/mg

as

per

activity

assay

protocol.DPP4/CD26Factor

IXENTPD3PRSS2CD73Carbonic

Anhydrase

IXFAPCD39ADAM17MMP-9CD38Chymotrypsin

CLOXL2PRSS3Kallikrein

8Cathepsin

BCathepsin

SADAM8/CD156aPIM1FLT3CDK9TAB1USP11PLK1MYT1CDK2RIPK1TYK2PLK4CDK1LRRK2ULK1PI3K

(p110

alpha/p85

alpha)FYNAMPKA2RIPK1USP11,

Active

(Cat#:

U511-380G)00120360480240Protein(ng)45,00090,000135,000180,000Activity(cpm)09273645The

specific

activity

of

USP11

was

determined

to

be

≥47nmol/min/mg

as

per

activity

assay

protocol.PLK1,

Active

(Cat#:

P41-10H)450,000360,000270,00018,0,00090,0000Activity(RLU)18Protein(ng)013412,0008,0004,00002Protein(ng)16,000Activity(RLU)MYT1,

Active

(Cat#:

M67-10G)The

specific

activity

of

MYT1

was

determined

to

be

9.5nmol/min/mg

as

per

activity

assay

protocol.56,0000020608010040Protein(ng)168,000112,000280,000224,000Activity(RLU)PIM1

Human靶点种属活性PIM1Human270

nmol/min/mgCDK2/CyclinE1Human104

nmol/min/mgCDK9/CyclinT1Human6

nmol/min/mgEGFRHuman＞70

nmol/min/mgPDGFRAHuman8

nmol/min/mgEphA2Human50

nmol/min/mgVEGFR2/KDRHuman10

nmol/min/mgc-METHuman10

nmol/min/mgFGFR2Human28

nmol/min/mg北京义翘神州04药物靶点研究相关试剂不同细胞群的CD抗原相关产品义翘神州开发了多种CD分子相关的试剂产品，包括重组蛋白、抗体、基因、ELISA试剂盒等。重组CD19/CD33蛋白CD52

CD40

CD37

CD23CD22

CD20

CD19

CD5CD分子CD抗原目前被广泛用于基础研究、免疫治疗、癌症治疗和药物靶点发现。CD抗原可以作为识别细胞类型或分化阶段的标志物，调节细胞的信号受体，以及细胞外基质中的细胞粘附因子。同时，CD抗原也是治疗性抗体的常用细胞表面靶点。16,000+CD分子相关试剂1,200+

重组蛋白2,500+

抗体10,000+

基因/cDNA200+

ELISA试剂盒qPCR

Primer/IP

Kit/Cell

Lysate覆盖9类种属340+分子高质量优惠的价格货号种属分子特性11880-H02WHuman稳定细胞株，HPLC、ELISA验证11880-H49H-BHumanCD19

生物素标记，ELISA验证8A0717-R08HRatELISA验证货号种属分子特性12238-HCCHHumanHPLC、ELISA验证12238-H05HHumanCD33HPLC、ELISA验证12238-H08HHumanHPLC、ELISA、BLI验证多应用验证的抗体不同细胞的CD标志物分子T

CellNK

CellStem

CellMonocyteGranulocytePlateletMacrophageErythrocyteEndothelialEpithelialB

CellDendritic

CellCD33CD56CD34CD14CD11bCD235aCD235aCD146CD326CD326CD31

CD106

CD146CD34CD335CD33CD66bCD66bCD41

CD61

CD62CD19

CD20CD19

CD20CD11c

CD123CD11c

CD123CD3

CD4

CD8CD41

CD9

CD62CD3

CD4

CD8人小鼠IHCCD71

(11020-R016)-human

placentaCD117-IHC-P:(11996-R351)-Breast

cancerIPCD114

(10218-MM03)-MCF7

cellsCD47

expressionplasmidTransfected

into

293H

adherentcells

Cat:

HG12283-CFIFCD340

(10004-R511)-SKBR3

cellsELISAFCGR2B

/

CD32b

protein543210OD450mm-B1E-4

1E-3

0.01

0.1

1

10Human

IgG1/Biotin

Con.

(ng/mL)bind

to

human

IgG1

(Cat:10259-H08H)北京义翘神州05药物靶点研究相关试剂CD分子T细胞,B细胞,NK细胞检测:CD3/CD16/CD56/CD19/CD45CD3/CD16/CD56/CD19/CD45可用于检测全血样本中成熟淋巴细胞亚群的比例：T淋巴细胞（CD3+）、B淋巴细胞（CD19+）、NK细胞（CD3-CD16+和/或CD56+）。更多流式抗体，请访问：/category/fcm-facs-antibodyT细胞检测:CD3/CD4/CD8/CD45

PanelCD3/CD4/CD8/CD45用于检测CD3、CD4和CD8的表达，用于分析白血病和淋巴的亚群，且可用于鉴定全血样本中成熟T淋巴细胞（CD3+）、辅助T淋巴细胞（CD3+CD4+）和细胞毒性T淋巴细胞（CD3+CD8+）亚群的百分比和绝对计数。105SSC-H

(106)0 0.4

0.8

1.2

1.6

1.8101

102

103

104CD45-PerCP-H-103.61050104CD3-APC-HCD19-FITC-H-103.6104

1050-103.61050104CD3-APC-HCD16+56-PE-H-103.2105.51040

1032.700.40.81.3SSC-H

(106)0.1

0.5

1

1.5

2FSC-H(106)-103.61041050APC-Hisotype-FITC-H-103.61041050-103.61041050APC-Hisotype-PE-H-103.2105.51040

10301.6

1.8SSC-H

(106)0.4

0.8

1.2101

102

103

104

105CD45-PerCP-H00.40.81.3SSC-H

(106)0.1

0.6

1.2

1.8

2.4

2.8FSC-H(106)101.5105.5103

104CD3-FITC-H101105CD45-PerCP-H102

103

104106.5-103.3

0104

105CD8-PE-H-103.6105.4CD4-APC-H0

104106.5-103.3

0104

105PE-Hisotype-APC-H-103.6104105.40101.5105.5103

104FITC-H101isotype-PerCP-H102

103

104105抗原分子标记货号CD45PerCP10086-MM05-CCD3APCCT026-R301-ACD19FITC11880-MM17-FCD16PE10389-MM22-PCD56PE10673-MM05-Pmouse

IgG1

isotypePEmouse

IgG1

isotypePerCPmouse

IgG1

isotypeFITC抗原分子标记货号CD45PerCP10086-MM05-CCD3FITCCT026-R301-FCD4APC10400-MM08-ACD8PE

10980-MM48-Pmouse

IgG1

isotypePerCPmouse

IgG1

isotype

APC东逝水北京义翘神州多次跨膜蛋白跨膜蛋白具有多种生理功能，包括蛋白连接、识别、转运、锚定和转导等，其功能的异常与诸多疾病相关。膜蛋白是重要的药物靶点，据统计，约50%药物的靶向分子为膜蛋白。然而，由于表达量低、体外不溶、纯化不稳定、难保持天然构象等问题的存在，限制了跨膜蛋白在药物开发方面的应用。义翘神州聚焦于多次跨膜蛋白产品的开发，成功搭建了三大技术平台，为药物早期研发提供重要的原材料。目前产品包括四次跨膜蛋白Claudin-6、Claudin-9、Claudin-18.1、Claudin-18.2，七次跨膜蛋白GPRC5D、CXCR4、SSTR2。06药物靶点研究相关试剂三大跨膜蛋白研发平台产品验证数据Human

GPRC5D-Nanodisc

Protein

(His

&

FLAG

Tag)

Cat#:24447-H18H-NAVLP技术平台 Detergent技术平台 Nanodisc技术平台50EC

=20.6

ng/mL0.11

10

100Anti-GPRC5D

antibody

Conc.

(ng/mL)03124Abs.(OD450nm-Blank)0 60

120

180

240

300

360

420

480Time

(s)0.80.70.60.50.40.30.20.10.0Respone

(nm)-100-50

0 50

100

150

200

250

300

350

400Time

(s)-5152535455Respone

(nm)Immobilized

Human

GPRC5D-NanodiscProtein

(His

&

FLAG

Tag)

at

5

µg/mL

(100µL/well)

can

bind

anti-HumanGPRC5D

antibody.Loaded

anti-GPRC5D

antibody

onProtein

A

Biosensor

binds

HumanGPRC5D-Nanodisc

Protein

(His

&

FLAGTag)

with

an

affinity

constant

of

0.782nM

asdeterminedin

BLI

assay

(ForteBioOctet

Red384).Captured

anti-GPRC5D

antibody

onanti-Human

IgG

Fc

via

CM5

Chip

bindsHuman

GPRC5D-Nanodisc

Protein

(His

&FLAG

Tag)

with

an

affinity

constant

of

9.609nMasdeterminedin

aSPR

assay

(BiacoreT200).北京义翘神州07药物靶点研究相关试剂膜蛋白产品列表推荐（部分）PIM1

Human靶点货号产品名称GPRC5D24447-HNAHHuman

GPRC5D-VLP

(Full

Length)

ProteinGPRC5D16658-HNAHHuman

CLDN6-VLP

(Full

Length)

ProteinCLDN18.230025-HNAHHuman

CLDN18.2-VLP

(Full

Length)

ProteinSSTR2A11644-HNAHHuman

SSTR2A-VLP

(Full

Length)

ProteinCD911029-H25HHuman

CD9-VLP

(Full

Length)

ProteinCCR811450-H82HHuman

CCR8-VLP

Protein

(Flag

&

His-Strep

Tag)CD2011007-HNAHHuman

CD20-VLP

(Full

Length)

ProteinGCGR30122-HNAHHuman

GCGR

Protein

(VLP)CXCR312979-H82HHuman

CXCR3

Protein

(VLP,

Full-Length,

Flag

&

His-Strep

Tag)GPRC5D5A4669-M25HMouse

GPRC5D-VLP

(Full

Length)

Protein

(Flag

Tag)CXCR612504-H82HHuman

CXCR6

Protein

(VLP,

Full-Length,

Flag

&

His-Strep

Tag)CCR611438-H22HHuman

CCR6

Protein

(VLP,

Full-Length,

Flag

Tag)GPRC5D24447-H18H-NAHuman

GPRC5D-Nanodisc

Protein

(His

&

FLAG

Tag)CLDN416358-H64H-NAHuman

CLDN4-Nanodisc

(Full

Length)

Protein,

(His

&

Strep

Tag)CLDN616658-H49H-NA-BHuman

CLDN6

-Nanodisc

Protein

(His

&

AVI

Tag),

BiotinylatedNewNewNewNew北京义翘神州免疫检查点相关试剂免疫检查点在癌症免疫疗法中发挥了重要作用。它们是一系列用于调节抗原识别的共刺激和抑制信号。癌细胞通过调节失常的免疫检查点信号巧妙地逃避免疫系统。因此，使用共刺激信号的激动剂或抑制信号的拮抗剂成为癌症治疗的有效方法。近年来，免疫检查点疗法取得了显著成功：CTLA-4和

PD1-PD-L1抑制剂已被批准用于癌症治疗，并显示出有效的疗效。关于其他免疫检查点的多项研究也已进入临床试验阶段，为战胜癌症带来了新的希望。义翘神州提供高质量免疫检查点相关蛋白，具有高纯度和良好的生物活性。纯度经过SEC-HPLC验证，生物活性通过ELISA和BLI等多种分析验证。08药物靶点研究相关试剂产品验证数据Cynomolgus

KIR3DL3

Protein

(His

Tag)Cat#:90983-C08HAnti-CTLA-4

therapyBlockade

of

PD-L1/PD-1

pathwayAnti-CTLA-4T

cellTCRCTLA-4

B7-1B7-2MHC-AgAPCPD-1

blockadeT

cellTCRPD-L1

blockadePD-1

PD-L1PD-L2PD-L1MHC-AgAPCLoaded

Biotinylated

Cynomolgus

KIR3DL3

Protein

on

SABiosensor,

can

bind

Recombinant

Cynomolgus

B7-H7/

HHLA2

Protein,

His

Tag

(Cat#:

90982-C08H)

with

an

affinity

constant

of

0.186

µM

as

determined

in

BLI

assay.Loaded

Recombinant

Cynomolgus

KIR3DL3

Protein,

His

Tag(Cat#:

90983-C08H)

onHis1K

Biosensor,

canbindRecombinantHuman

B7-H7/HHLA2

Protein,

hFc

Tag

(Cat#:

16139-H02H)

withan

affinity

constant

of

18.3

nM

as

determined

in

BLI

assay.0.200.250.150.100.050.00Response（nm）060120180240300Time（s）0.200.150.100.05Response（nm）Time（s）0.00060120180240北京义翘神州Cynomolgus

B7-H7/HHLA2

Protein

(His

Tag)Cat#:90982-C08H09药物靶点研究相关试剂蛋白分子列表（部分）PDCD1PD-L1PD-L2TIGITCD155/PVRPVRIGPVRL1/NECTIN1Nectin-2Nectin

3NECTIN4/Nectin

4CD96CD226CD1374-1BBL/TNFSF9CTLA-4CD28B7-1CD86CEACAM1CEACAM3CEACAM5CEACAM6CD66bLAG3CD47SIRP

alphaSIRP

gamma/SIRPGCD40

LigandCD40OX40OX40L/TNFSF4B7-H3B7-H3(4ig)B7-H4VISTAB7-H6HHLA2NKp44/NCR2NKp30/NCR3TMIGD2LILRA1/LIR-6/CD85iLILRA2LILRA3LILRA4/CD85gLILRA5LILRA6LILRB1ILT4LILRB3ILT3LILRB5/CD85cTIM-3CD30/TNFRSF8CD30LICOSICOS

ligandCD70CD27TNFSF18GITRLIGHTCD160BTLAHVEMSLAM/CD150CD48CD2292B4/CD244CD84SLAMF6SLAMF7/CD319LAIR1LAIR2SIGLEC5CD22CD33SIGLEC6SIGLEC10SIGLEC15BTN3A1BTN3A3HMGB1RAGENKG2ANKG2DKIR2DL1KIR2DL3KIR2DL4KIR2DL5KIR3DL3MICAMICBDR3中和抗体种属分子应用货号HumanHumanPD1PD1Neutralization,

BlockNeutralization,

Block10377-HN9410377-HF06HumanPD1Block10377-mhT28HumanPD-L1Block10084-R639混合淋巴细胞反应（MLR）评估抗人PD1抗体（Cat#:

10377-HN94）对IFN-gamma以及IL-2生产的影响。Loaded

Biotinylated

Cynomolgus

KIR3DL3

Protein

on

SABiosensor,

can

bind

Recombinant

Cynomolgus

B7-H7/HHLA2Protein,His

Tag

(Cat#:

90982-C08H)

with

an

affinity

constantof

0.186

µM

as

determinedin

BLIassay.≥

90%

as

determined

by

SEC-HPLC.Time

[min]140120100806040200mAU4.0924.8695.9330.200.150.100.050.00Response（nm）0

1

2

3

4

5

6

7

8 9

10

11

12

13

14

15

0

60120Time（s）180240北京义翘神州10药物靶点研究相关试剂CAR-T细胞疗法相关试剂生物活性验证标记蛋白列表（部分）更多靶点蛋白嵌合抗原受体T细胞治疗（CAR-T

细胞治疗）已广泛应用于癌症免疫治疗领域。Anti-BCMA-CAR+

0.04%Anti-BCMA-CAR+

59.6%FITC

BCMA

(Cat#:

10620-H03H-F)293

cells

were

lentivirally

transduced

with

anti-BCMA

CAR.Flow

cytometric

analysis

was

performed

withFITC-conjugated

recombinant

human

BCMA.Non-transduced

293

cells

were

used

as

a

control

(left).SSCSSCAnti-CD22-CAR+

0.18%Anti-CD22-CAR+

40.1%PE-CD22

(Cat#:

11958-H08H-P)Human

T

cells

were

lentivirally

transduced

with

anti-CD22CAR.

Flow

cytometric

analysis

was

performed

withPE-conjugated

recombinant

human

CD22.

Non-transduced

T

cells

were

used

as

a

control

(left).SSCSSCAnti-BCMA-CAR+

0.02%Anti-BCMA-CAR+

63.1%PE

BCMA

(Cat#:

10620-H03H-P)293

cells

were

lentivirally

transduced

with

anti-BCMA

CAR.Flow

cytometric

analysis

was

performed

withPE-conjugated

recombinant

human

BCMA.Non-transduced

293

cells

were

used

as

a

control

(left).SSCSSC分子标记物BCMAPE/FITC/BiotinylatedCD22PE/BiotinylatedCD33PE/FITC/BiotinylatedCD38PE/FITC/BiotinylatedROR1BiotinylatedEpCAMBiotinylatedEGFRBiotinylatedHer2/ERBB2BiotinylatedVEGFR2/KDRBiotinylatedULBP1BiotinylatedULBP2BiotinylatedCD19BCMACD22CD33CD38Glypican

3PD-L1CEACAM5FOLR1PD-1EGFRHer2/ERBB2CD30/TNFRSF8FAPIL3RANCAMULBP1c-METROR1EpCAMMesothelinCD20CD5

CD7VEGFR2/KDRMUC1CD70Syndecan-1/CD138Carbonic

Anhydrase

IXIL1RAP/IL-1RAcPULBP2EphA2PSMAL1CAMIL13RA23.

T

cell

engineering1.

Blood

collection2.

Isolation

andactivation

of

T

cells4.

CAR-T

cellexpansion5.

Pretreatment

andCAR-T

cell

infusionT

cellPGK

scFv

CD28

CD3ζ北京义翘神州流式应用抗体T细胞：CD3,CD4,CD8,CD4511药物靶点研究相关试剂靶点标记物货号CD45PerCP10086-MM05-CCD3FITCCT026-R301-FCD4APC10400-MM08-ACD8PE10980-MM48-PMouse

IgG1

isotypePerCPMouse

IgG1

isotypeAPC注：了解更多流式抗体，请访问靶向CD3/CD4/CD8/CD45靶点的流式抗体用于鉴定全血中CD3+成熟T细胞以及CD3+/CD8+抑制性/毒性T细胞亚群的百分比和绝对计数值。1011050SSC-H

(106)0.4

0.8

1.2

1.6

1.8102

103

104CD45-PerCP-H01.3SSC-H

(106)0.4

0.80.1

0.6

1.2

1.8 2.4

2.8FSC-H(106)101.5105.5CD45-PerCP-H103

104CD3-FITC-H101104

105102103106.5-103.3

0104

105CD8-PE-H-103.6CD4-APC-H104105.40106.5-103.3

0104

105PE-Hisotype-APC-H-103.6104105.40101.5103104105.5FITC-Hisotype-PerCP-H10110210310410510110501.6

1.8SSC-H

(106)0.4

0.8

1.2102

103

104CD45-PerCP-H101.5105.5CD45-PerCP-H103

104CD3-FITC-H101104105102

103106.5-103.3

0104

105CD8-PE-H-103.6CD4-APC-H104105.40义翘神州其他商业品牌北京义翘神州12药物靶点研究相关试剂细胞因子细胞活性验证ELISA试剂盒（可用于细胞因子检测）依托于先进的重组蛋白、抗体研发生产以及质量检测平台，义翘神州开发了一系列可用于准确定量血浆、血清、细胞培养上清以及更多生物样品中细胞因子含量的ELISA检测试剂盒。中和抗体重组细胞因子列表（部分）8大质控标准，打造高精端ELISA试剂盒检测限

精密度

回收率评估灵敏度

评估重复实验误差

评估准确度热门细胞因子ELISA试剂盒—即用型种属分子货号线性范围(pg/mL)MouseIL1ASEK501146.25-400HumanIL4SEK118467.81-500HumanIL5SEKA156733.91-250HumanIL6SEKB103959.38-600HumanIL8SEK1009811.72-750HumanIL10SEKA1094714.06-900HumanTNFαSEKA1060239.06-2500MouseTNFαSEK5034931.25-2000FerretTNFαSEK6000278.13-5000HumanIFNγSEKA1172521.88-1400种属分子货号线性范围(pg/mL)检测样品MouseIL1AKIT501146.56-420S,CHumanIL2KIT1184818.75-1200S,

C,

PHumanIL4KIT1184610.94-700CHumanIL5KIT156734.69-300CHumanIL6KIT10395A5.47-350S,CHumanIL8KIT100982.5-160CHumanIL10K